Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, evaluates the impact of the COVID-19 pandemic on the treatment and management of acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).